•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A07245 Summary:

BILL NOA07245A
 
SAME ASSAME AS S04370-B
 
SPONSORGottfried
 
COSPNSRMcDonald, Frontus, Barron, Englebright, Perry, Rivera JD, Griffin, Davila, Burdick, Simon, Sillitti, Barnwell, Epstein, Rosenthal L, Wallace, Lupardo, Gonzalez-Rojas, Paulin, Galef, Thiele, Abinanti, Bichotte Hermelyn, Steck, Solages, Stirpe, Smith, Reyes, Niou, Forrest, Lavine, Jean-Pierre, Jackson, Gunther, Hevesi, Dinowitz, Quart, Mamdani, Glick
 
MLTSPNSR
 
Add Art 2-A Title IV §§282 & 283, Pub Health L
 
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
Go to top